Clusterin is a chaperone protein that is upregulated in response to chemotherapy and might mediate resistance, Now, data from SYNERGY, a phase III randomized-controlled trial indicate that custirsen, an antisense oligonucleotide that inhibits clusterin production, does not improve the efficacy of docetaxel plus prednisone in patients with metastatic, castration-resistant prostate cancer.
Change history
04 May 2017
A previous version of this article contained a typographical error. This has now been corrected online and in print.
References
Chi, K. N. et al. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(17)30168-7 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Custirsen fails to improve outcomes. Nat Rev Urol 14, 327 (2017). https://doi.org/10.1038/nrurol.2017.51
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.51